flutamide has been researched along with Disease Exacerbation in 61 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis." | 5.08 | PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. ( Casselman, J; Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W; Van Velthoven, R, 1997) |
| "The flutamide treated CaP cases had increased discriminant function scores in 19 out of 24 cases (79%) and an increase of the mean score by 43%; the 5 cases with lower scores involved only minor reductions." | 2.78 | A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. ( Alberts, DS; Bartels, HG; Bartels, PH; Carmignani, G; DeCensi, A; Decobelli, O; Hurle, R; Maffezzini, M; Mazzucchelli, R; Montironi, R; Puntoni, M, 2013) |
| "In all, 38 patients have had disease progression (30/55, 55%) or died without progression (8/55, 15%) for a 10-year progression-free survival (PFS) estimate of 40% (95% CI 27-53)." | 2.77 | Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. ( Berglund, RK; Canby-Hagino, ED; Carroll, PR; Crawford, ED; deVere White, R; Haas, GP; Hemstreet, GP; Klein, EA; Lowe, BA; Powell, IJ; Tangen, CM; Thompson, IM, 2012) |
| "The vast majority of residual tumors were poorly differentiated (Gleason score ≥ 8)." | 2.76 | Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. ( Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A, 2011) |
| "For good prognosis metastatic prostate cancer patients under anti-androgen treatment, PSA response at 6 months with cut-off levels of < or = 1 ng/ml and < or = 10 ng/ml is prognostic for survival." | 2.71 | Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). ( Collette, L; de Reijke, TM; Schröder, FH, 2003) |
| "The number of patients who died of prostate cancer up to this time is insufficient for a definitive analysis of specific survival." | 2.71 | Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. ( Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P, 2004) |
| "Men with histologically confirmed prostate cancer not amenable to curative surgery or radiation therapy were eligible for the study if they had radiographic or PSA progression on at least one antiandrogen (not nilutamide) despite continued androgen suppression and standard antiandrogen withdrawal periods." | 2.71 | A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. ( Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ, 2005) |
| "After disease progression, patients treated with B were assigned to castration." | 2.70 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E, 2002) |
| "The primary clinical events were disease progression and survival." | 2.69 | Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. ( Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1999) |
| "After disease progression, patients treated with bicalutamide were assigned to castration." | 2.69 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G, 1999) |
| "Regarding local disease progression, the advantage for the use of NHT approached but did not reach statistical significance:18 of 189 patients (10%) in the NHT group and 33 of 209 patients (16%) in the RP group (P = 0." | 2.69 | Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. ( Debruyne, FM; Witjes, WP, 2000) |
| "Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL." | 2.68 | Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B, 1997) |
| "Flutamide was metabolised to 2-hydroxyflutamide achieving steady-state plasma levels across the study duration and reached the spinal cord at pharmacologically active concentrations." | 1.51 | Androgen receptor antagonism accelerates disease onset in the SOD1 ( Boon, WC; Chiam, MDF; Djouma, E; Lau, CL; McLeod, VM; Roessner, U; Rupasinghe, TW; Turner, BJ, 2019) |
| "The progression of prostate cancer from an organ-confined, androgen-sensitive disease to a metastatic one is associated with dysregulation of androgen receptor (AR)-regulated target genes and with a decrease in insulin-like growth factor-I receptor (IGF1R) expression." | 1.36 | Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. ( Bentov, I; Plymate, SR; Schayek, H; Sun, S; Werner, H, 2010) |
| "With progress of type 1 diabetes, decrement of AR expression in diabetic mice contributes to prohibit beta-cells from apoptosis, and is strongly associated with beta-cell proliferation." | 1.35 | Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta-cell in type 1 diabetes mellitus. ( Huo, YW; Li, RJ; Qiu, SD; Tian, H; Wang, HX; Wang, LR, 2008) |
| "Patients with locally advanced prostate cancer have a high risk of progression after RP as single therapy." | 1.35 | Long-term follow-up after triple treatment of prostate cancer stage pT3. ( Aus, G; Klintenberg, C; Madsen, M; Mäkelä, E; Palmqvist, E; Schelin, S, 2009) |
| "This suggests that HF promoted prostate cancer cell growth is COX-2 dependent and this HF-COX-2 activation pathway can account for one reason of CAB therapy failure." | 1.35 | A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. ( Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S, 2008) |
| "Lethal prostate cancers often become androgen-independent due to androgen receptor (AR) overexpression." | 1.34 | Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells. ( Benbrahim-Tallaa, L; Liu, J; Waalkes, MP; Webber, MM, 2007) |
| "Imaging of tumors with a cooled charge-coupled device camera revealed that the response of AdTSTA to flutamide is more sensitive and robust than serum PSA measurements." | 1.33 | Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. ( Carey, M; Gambhir, SS; Ilagan, R; Iyer, M; Le, K; Pottratz, J; Salas, S; Wu, L; Zhang, LJ, 2005) |
| "Four patients suffered bone fractures, none pathological." | 1.31 | A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. ( Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R, 2000) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later." | 1.31 | Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. ( Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T, 2002) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | 1.30 | Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. ( Lubos, W; Schmeller, N, 1997) |
| "Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily." | 1.30 | Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. ( Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L, 1997) |
| "Flutamide withdrawal was undertaken at the time of disease progression." | 1.29 | The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. ( Small, EJ; Srinivas, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (37.70) | 18.2507 |
| 2000's | 26 (42.62) | 29.6817 |
| 2010's | 12 (19.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muramatsu, T | 1 |
| Funahashi, Y | 1 |
| Yamamoto, A | 1 |
| Sassa, N | 1 |
| Matsukawa, Y | 1 |
| Gotoh, M | 1 |
| Iguchi, T | 1 |
| Tamada, S | 1 |
| Kato, M | 1 |
| Yasuda, S | 1 |
| Otoshi, T | 1 |
| Hamada, K | 1 |
| Yamasaki, T | 1 |
| Nakatani, T | 1 |
| McLeod, VM | 1 |
| Lau, CL | 1 |
| Chiam, MDF | 1 |
| Rupasinghe, TW | 1 |
| Roessner, U | 1 |
| Djouma, E | 1 |
| Boon, WC | 1 |
| Turner, BJ | 1 |
| Kunath, F | 1 |
| Grobe, HR | 1 |
| Rücker, G | 1 |
| Motschall, E | 1 |
| Antes, G | 1 |
| Dahm, P | 1 |
| Wullich, B | 1 |
| Meerpohl, JJ | 1 |
| Shang, Z | 1 |
| Li, Y | 1 |
| Zhang, M | 1 |
| Tian, J | 1 |
| Han, R | 1 |
| Shyr, CR | 1 |
| Messing, E | 1 |
| Yeh, S | 1 |
| Niu, Y | 1 |
| Chang, C | 2 |
| Murray, NP | 1 |
| Reyes, E | 1 |
| Fuentealba, C | 1 |
| Jacob, O | 1 |
| Orellana, N | 1 |
| Davis, JP | 1 |
| Salmon, M | 1 |
| Pope, NH | 1 |
| Lu, G | 1 |
| Su, G | 1 |
| Meher, A | 1 |
| Ailawadi, G | 1 |
| Upchurch, GR | 1 |
| Li, RJ | 1 |
| Qiu, SD | 1 |
| Wang, HX | 1 |
| Tian, H | 1 |
| Wang, LR | 1 |
| Huo, YW | 1 |
| Schelin, S | 1 |
| Madsen, M | 1 |
| Palmqvist, E | 1 |
| Mäkelä, E | 1 |
| Klintenberg, C | 1 |
| Aus, G | 1 |
| Schayek, H | 1 |
| Bentov, I | 1 |
| Sun, S | 1 |
| Plymate, SR | 1 |
| Werner, H | 1 |
| Solberg, A | 1 |
| Haugen, OA | 1 |
| Viset, T | 1 |
| Bergh, A | 2 |
| Tasdemir, I | 1 |
| Ahlgren, G | 1 |
| Widmark, A | 1 |
| Angelsen, A | 1 |
| Montironi, R | 1 |
| Bartels, PH | 1 |
| DeCensi, A | 1 |
| Puntoni, M | 1 |
| Hurle, R | 1 |
| Decobelli, O | 1 |
| Carmignani, G | 3 |
| Mazzucchelli, R | 1 |
| Bartels, HG | 1 |
| Alberts, DS | 1 |
| Maffezzini, M | 1 |
| Jain, HV | 1 |
| Clinton, SK | 1 |
| Bhinder, A | 1 |
| Friedman, A | 1 |
| Berglund, RK | 1 |
| Tangen, CM | 1 |
| Powell, IJ | 1 |
| Lowe, BA | 1 |
| Haas, GP | 1 |
| Carroll, PR | 1 |
| Canby-Hagino, ED | 1 |
| deVere White, R | 1 |
| Hemstreet, GP | 1 |
| Crawford, ED | 3 |
| Thompson, IM | 2 |
| Klein, EA | 2 |
| Boccardo, F | 2 |
| Barichello, M | 2 |
| Battaglia, M | 2 |
| Comeri, G | 2 |
| Ferraris, V | 2 |
| Lilliu, S | 2 |
| Montefiore, F | 2 |
| Portoghese, F | 2 |
| Cortellini, P | 1 |
| Rigatti, P | 1 |
| Usai, E | 1 |
| Rubagotti, A | 2 |
| Hedlund, PO | 1 |
| Ala-Opas, M | 1 |
| Brekkan, E | 1 |
| Damber, JE | 1 |
| Damber, L | 1 |
| Hagerman, I | 1 |
| Haukaas, S | 1 |
| Henriksson, P | 1 |
| Iversen, P | 1 |
| Pousette, A | 1 |
| Rasmussen, F | 1 |
| Salo, J | 1 |
| Vaage, S | 1 |
| Varenhorst, E | 1 |
| Kosugi, M | 1 |
| Hanawa, Y | 1 |
| Momma, T | 1 |
| Saito, S | 1 |
| Hirose, S | 1 |
| Oh, WK | 1 |
| Manola, J | 1 |
| Bittmann, L | 1 |
| Brufsky, A | 1 |
| Kaplan, ID | 1 |
| Smith, MR | 1 |
| Kaufman, DS | 1 |
| Kantoff, PW | 1 |
| Collette, L | 3 |
| de Reijke, TM | 2 |
| Schröder, FH | 2 |
| Barqawi, A | 1 |
| Akduman, B | 1 |
| Abouelfadel, Z | 1 |
| Robischon, M | 1 |
| Whelan, P | 2 |
| Kurth, KH | 1 |
| Pavone-Macaluso, M | 1 |
| Mattelaer, J | 2 |
| van Velthoven, RF | 1 |
| Debois, M | 1 |
| de Leval, J | 1 |
| Boca, P | 1 |
| Yousef, E | 1 |
| Nicolas, H | 1 |
| Jeukenne, M | 1 |
| Seidel, L | 1 |
| Bouffioux, C | 1 |
| Coppens, L | 1 |
| Bonnet, P | 1 |
| Andrianne, R | 1 |
| Wlatregny, D | 1 |
| Sato, N | 1 |
| Akakura, K | 1 |
| Isaka, S | 1 |
| Nakatsu, H | 1 |
| Tanaka, M | 1 |
| Ito, H | 1 |
| Masai, M | 1 |
| Nagao, S | 1 |
| Kusaka, M | 1 |
| Nishii, K | 1 |
| Marunouchi, T | 1 |
| Kurahashi, H | 1 |
| Takahashi, H | 1 |
| Grantham, J | 1 |
| Davis, NB | 1 |
| Ryan, CW | 1 |
| Stadler, WM | 1 |
| Vogelzang, NJ | 3 |
| Ilagan, R | 1 |
| Zhang, LJ | 1 |
| Pottratz, J | 1 |
| Le, K | 1 |
| Salas, S | 1 |
| Iyer, M | 1 |
| Wu, L | 1 |
| Gambhir, SS | 1 |
| Carey, M | 1 |
| Ohlson, N | 1 |
| Nygren, K | 1 |
| Stattin, P | 1 |
| Wikström, P | 1 |
| Benbrahim-Tallaa, L | 1 |
| Liu, J | 1 |
| Webber, MM | 1 |
| Waalkes, MP | 1 |
| Cho, YM | 1 |
| Takahashi, S | 1 |
| Asamoto, M | 1 |
| Suzuki, S | 1 |
| Tang, M | 1 |
| Shirai, T | 1 |
| Roach, M | 1 |
| De Silvio, M | 1 |
| Rebbick, T | 1 |
| Grignon, D | 1 |
| Rotman, M | 1 |
| Wolkov, H | 1 |
| Fisher, B | 1 |
| Hanks, G | 1 |
| Shipley, WU | 2 |
| Pollack, A | 1 |
| Sandler, H | 1 |
| Watkins-Bruner, D | 1 |
| Nishiyama, T | 1 |
| Ikarashi, T | 1 |
| Hashimoto, Y | 1 |
| Wako, K | 1 |
| Takahashi, K | 1 |
| Cai, Y | 1 |
| Lee, YF | 1 |
| Li, G | 1 |
| Liu, S | 1 |
| Bao, BY | 1 |
| Huang, J | 1 |
| Hsu, CL | 1 |
| Small, EJ | 2 |
| Srinivas, S | 1 |
| Bennett, CL | 1 |
| Matchar, D | 1 |
| McCrory, D | 1 |
| McLeod, DG | 2 |
| Hillner, BE | 1 |
| Zalcberg, JR | 1 |
| Raghaven, D | 1 |
| Marshall, V | 1 |
| Thompson, PJ | 1 |
| Grignon, DJ | 1 |
| Caplan, R | 1 |
| Sarkar, FH | 1 |
| Lawton, CA | 1 |
| Hammond, EH | 1 |
| Pilepich, MV | 1 |
| Forman, JD | 1 |
| Mesic, J | 1 |
| Fu, KK | 1 |
| Abrams, RA | 1 |
| Pajak, TF | 1 |
| Cox, JD | 1 |
| Albertsen, PC | 1 |
| Aaronson, NK | 1 |
| Muller, MJ | 1 |
| Keller, SD | 1 |
| Ware, JE | 1 |
| Schmeller, N | 1 |
| Lubos, W | 1 |
| Scher, HI | 2 |
| Kolvenbag, GJ | 3 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Figg, WD | 2 |
| Kroog, G | 1 |
| Duray, P | 1 |
| Walther, MM | 1 |
| Patronas, N | 1 |
| Sartor, O | 3 |
| Reed, E | 2 |
| Krijnen, JL | 1 |
| Bogdanowicz, JF | 2 |
| Seldenrijk, CA | 1 |
| Mulder, PG | 1 |
| van der Kwast, TH | 2 |
| Dawson, NA | 1 |
| Cooper, MR | 1 |
| Bergan, RC | 1 |
| Senderowicz, AM | 1 |
| Steinberg, SM | 1 |
| Tompkins, A | 1 |
| Weinberger, B | 1 |
| Sausville, EA | 1 |
| Myers, CE | 1 |
| Liebertz, C | 1 |
| Kelly, WK | 1 |
| Mazumdar, M | 1 |
| Brett, C | 1 |
| Schwartz, L | 1 |
| Kolvenbag, G | 1 |
| Shapiro, L | 1 |
| Schwartz, M | 1 |
| Noordzij, MA | 1 |
| van Krimpen, C | 1 |
| van Steenbrugge, GJ | 1 |
| Oosterlinck, W | 1 |
| Casselman, J | 1 |
| Van Velthoven, R | 1 |
| Derde, MP | 1 |
| Kaufman, L | 1 |
| Eastham, JA | 1 |
| Denis, LJ | 1 |
| Keuppens, F | 1 |
| Smith, PH | 1 |
| de Moura, JL | 1 |
| Newling, D | 1 |
| Bono, A | 1 |
| Sylvester, R | 1 |
| Breul, J | 1 |
| Paul, R | 1 |
| Bono, AV | 1 |
| DiSilverio, F | 1 |
| Robustelli della Cuna, G | 1 |
| Benvenuti, C | 1 |
| Brausi, M | 2 |
| Ferrari, P | 1 |
| Gibba, A | 1 |
| Galli, L | 1 |
| Longmore, L | 1 |
| Foley, JP | 1 |
| Rozanski, TA | 1 |
| Higgins, B | 1 |
| Sarosdy, MF | 2 |
| Schellhammer, PF | 2 |
| Sharifi, R | 2 |
| Block, NL | 2 |
| Soloway, MS | 2 |
| Venner, PM | 2 |
| Patterson, AL | 2 |
| Chodak, GW | 1 |
| Schellenger, JJ | 1 |
| Collinson, MP | 1 |
| Daniel, F | 1 |
| Tyrrell, CJ | 1 |
| Teasdale, C | 1 |
| Kelley, RP | 1 |
| Conti, G | 1 |
| Cruciani, G | 1 |
| Dammino, S | 1 |
| Delliponti, U | 1 |
| Ditonno, P | 1 |
| Spano, G | 1 |
| Egawa, S | 1 |
| Takashima, R | 1 |
| Matsumoto, K | 1 |
| Mizoguchi, H | 1 |
| Kuwao, S | 1 |
| Baba, S | 1 |
| Klotz, L | 1 |
| Gleave, M | 1 |
| Goldenberg, SL | 1 |
| Debruyne, FM | 1 |
| Witjes, WP | 1 |
| Fosså, SD | 1 |
| Slee, PH | 1 |
| Horenblas, S | 1 |
| Hall, RR | 1 |
| Hetherington, JW | 1 |
| Aaronson, N | 1 |
| Rapoport, J | 1 |
| Furuya, Y | 1 |
| Nozaki, T | 1 |
| Nagakawa, O | 1 |
| Fuse, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for flutamide and Disease Exacerbation
| Article | Year |
|---|---|
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gon | 2014 |
[Anti-androgen withdrawal syndrome].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; | 1998 |
Neoadjuvant hormone therapy: the Canadian trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2000 |
24 trials available for flutamide and Disease Exacerbation
| Article | Year |
|---|---|
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality The | 2011 |
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry.
Topics: 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Cell Nucleus; Cost-Benefit Analysis; Disea | 2013 |
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Therapy, Comb | 2012 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Disease Progre | 2002 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antin | 2003 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyprote | 2003 |
The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy | 2003 |
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide; | 2004 |
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2002 |
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progres | 2004 |
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; F | 2005 |
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black People; Cytochrome P-450 CYP3A; C | 2007 |
Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progres | 1996 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Belgium; Carcinom | 1997 |
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1998 |
Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Disease Pr | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant | 1998 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agent | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; An | 1999 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease | 2000 |
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Disease Progression; Europe; Flutamide; | 2001 |
34 other studies available for flutamide and Disease Exacerbation
| Article | Year |
|---|---|
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostat | 2019 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Benzamides; Disease Progressio | 2019 |
Androgen receptor antagonism accelerates disease onset in the SOD1
Topics: Amyotrophic Lateral Sclerosis; Androgen Receptor Antagonists; Animals; Disease Models, Animal; Disea | 2019 |
Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cell Lin | 2015 |
Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence.
Topics: Age Factors; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Blood Vessels; Disease Pro | 2015 |
Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.
Topics: Androgen Antagonists; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Cytokines; Disease Mode | 2016 |
Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta-cell in type 1 diabetes mellitus.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Apoptosis; Cell Proliferati | 2008 |
Long-term follow-up after triple treatment of prostate cancer stage pT3.
Topics: Adult; Aged; Androgen Antagonists; Combined Modality Therapy; Disease Progression; Flutamide; Follow | 2009 |
Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.
Topics: Androgen Antagonists; Androgens; Azacitidine; Blotting, Western; CpG Islands; Decitabine; Dihydrotes | 2010 |
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.
Topics: Algorithms; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cells, Cultured; Disease | 2011 |
[Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Carcinoma, Neuroendocrine; Cell Differentiati | 2003 |
Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
Topics: Androgen Antagonists; Animals; Cell Proliferation; Dihydrotestosterone; Disease Models, Animal; Dise | 2005 |
Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model.
Topics: Adenoviridae; Androgens; Animals; Antineoplastic Agents, Hormonal; Binding Sites; Chromatin Immunopr | 2005 |
The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Apoptosis; Biopsy; Chi-Square Distribution; Combined | 2006 |
Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
Topics: Androgen Antagonists; Androgens; Cadmium; Cell Line, Transformed; Cell Proliferation; Cell Transform | 2007 |
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor | 2007 |
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers, Tumor; Dihydrotestosterone; Disease Progr | 2007 |
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2008 |
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Moda | 1995 |
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Cost-Benefit Analysis; Disease Pro | 1996 |
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cl | 1997 |
Health-related quality of life among patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Combined Chemothera | 1997 |
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progressio | 1997 |
The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Male; | 1997 |
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic Agents, Hormona | 1997 |
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cell Differentiation; Dise | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; | 1997 |
The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease Progression; Disease-Free Survival; Flutamide | 1997 |
Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Prog | 1998 |
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brac | 1998 |
Response of carcinoma of the prostate to withdrawal of flutamide.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Goserel | 1993 |
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic | 2000 |
Oncogenic osteomalacia.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Cholecalciferol; Disease Progression; Fatal Outcome; Flutamide | 2000 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Ac | 2002 |